<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Monoclonal B cell lymphocytosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Monoclonal B cell lymphocytosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Monoclonal B cell lymphocytosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Matthew S Davids, MD, MMSc</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter Newburger, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1912503487"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Monoclonal B cell lymphocytosis (MBL) refers to a monoclonal population of B lymphocytes &lt;5000 cells/microL (&lt;5 x 10<sup>9</sup>/L) in peripheral blood for ≥3 months, without other features of a B cell lymphoproliferative disorder (eg, lymphadenopathy, organomegaly, cytopenias, or extramedullary involvement) [<a href="#rid1">1,2</a>].</p><p>This topic will discuss the epidemiology, evaluation, diagnosis, prognosis, and management of MBL.</p><p>Evaluation of lymphocytosis in the adult and in the child, and clinical features and diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/104124.html" rel="external">"Approach to the adult with lymphocytosis or lymphocytopenia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/8387.html" rel="external">"Approach to the child with lymphocytosis or lymphocytopenia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4513.html" rel="external">"Clinical features and diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma"</a>.)</p><p></p><p class="headingAnchor" id="H1064989602"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The incidence of MBL increases with age, and one study reported that the prevalence of MBL is 1.5-fold (95% CI 1.1-2.1) greater in men than women, on an age-adjusted basis [<a href="#rid3">3</a>]. The prevalence of MBL is &gt;100-fold greater than chronic lymphocytic leukemia (CLL), the most common leukemia in adults [<a href="#rid4">4,5</a>]. The age-dependent increase in MBL incidence is observed in all categories of MBL [<a href="#rid3">3,6</a>]. (See <a class="local">'Classification and prognosis'</a> below.)</p><p>Population-based screening studies (using four- or five-color flow cytometry) have reported the following prevalence rates [<a href="#rid7">7,8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>&lt;40 years old: 0.2 to 0.3 percent</p><p class="bulletIndent1"><span class="glyph">●</span>≥40 to ≤60 years old: 3.5 to 6.7 percent</p><p class="bulletIndent1"><span class="glyph">●</span>&gt;60 years old: 5 to 9 percent</p><p></p><p>Reports of the prevalence of MBL are influenced by the sensitivity of the assay used to detect B cell clonality. Using highly sensitive techniques (eight-color flow cytometry), one study reported MBL in at least one-fifth of 608 healthy adults over age 60 years, and in more than three-quarters of individuals over age 90 [<a href="#rid9">9</a>]. Another study that used eight-color flow cytometry reported MBL in 12 percent of 984 asymptomatic adults ≥40 years old [<a href="#rid10">10</a>]. The effect of assay sensitivity on detection of MBL is discussed below. (See <a class="local">'Sensitivity'</a> below.)</p><p>Family studies and genetic markers suggest an inherited contribution to MBL development. In first-degree relatives of patients with CLL, MBL was detected in 14 to 22 percent of individuals with normal blood counts; the relative risk of MBL was increased fourfold overall, and 17-fold in younger adults (16 to 40 years old) [<a href="#rid11">11-13</a>]. Both familial and sporadic forms of CLL are associated with a higher incidence of MBL in relatives [<a href="#rid14">14</a>]. Genetic predisposition to MBL is also indicated by an association between MBL and single nucleotide polymorphisms [<a href="#rid15">15,16</a>]. Familial forms of CLL are discussed separately. (See  <a class="medical medical_review" href="/d/html/4513.html" rel="external">"Clinical features and diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma", section on 'Family studies'</a>.)</p><p>Population-based studies have reported an association of MBL with chronic hepatitis C virus infection and with pneumonia; conversely, a lower incidence of MBL was reported among patients vaccinated for influenza or pneumonia [<a href="#rid17">17-19</a>].</p><p class="headingAnchor" id="H1268582765"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>MBL may be encountered as an incidental finding in the setting of lymphocytosis, or in the assessment of another clinical disorder. Evaluation of a patient with lymphocytosis is described separately. (See  <a class="medical medical_review" href="/d/html/104124.html" rel="external">"Approach to the adult with lymphocytosis or lymphocytopenia"</a>.)</p><p>Evaluation of MBL should seek evidence of associated conditions (eg, lymphoma or other lymphoproliferative disorder, autoimmune condition, infection), and should include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>History</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Active or prior infections (eg, hepatitis, pneumonia) or inflammatory processes (autoimmune conditions)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>History of hematologic malignancy (eg, lymphoma, leukemia) or related clinical findings (eg, unexplained lymphadenopathy, fevers, sweats, weight loss)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Medications</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Family history of chronic lymphocytic leukemia (CLL) or other lymphoproliferative disorders</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physical examination</strong> – The physical examination should seek evidence of infection, inflammation, or malignancy, such as fever, lymphadenopathy, hepatosplenomegaly, joint redness, abdominal pain, and lung findings.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complete blood count (CBC) with differential</strong> – MBL may be detected in the setting of lymphocytosis (ie, ≥4000 lymphocytes/microL), or in a patient with a normal lymphocyte count.</p><p></p><p class="bulletIndent1">Findings from the CBC may suggest an associated condition:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Neutrophilia or monocytosis, which may be associated with infections, or inflammatory processes. (See  <a class="medical medical_review" href="/d/html/8381.html" rel="external">"Approach to the patient with neutrophilia"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Eosinophilia and/or basophilia, which may be associated with allergic, infectious, or inflammatory conditions. (See  <a class="medical medical_review" href="/d/html/5691.html" rel="external">"Approach to the patient with unexplained eosinophilia"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Anemia (eg, hemolytic anemia, anemia of chronic disease from underlying inflammation or infections). (See  <a class="medical medical_review" href="/d/html/7133.html" rel="external">"Diagnostic approach to anemia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blood smear</strong> – The blood smear should be reviewed to assess lymphocyte morphology and other lineages. Lymphocytes in MBL have no distinguishing appearance and typically appear as small, mature mononuclear cells. (See  <a class="medical medical_review" href="/d/html/4513.html" rel="external">"Clinical features and diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma", section on 'Peripheral smear'</a>.)</p><p></p><p>The diagnosis of MBL does <strong>not</strong> require bone marrow examination or imaging [<a href="#rid1">1</a>].</p><p>Documentation of B cell clonality is described below. (See <a class="local">'Flow cytometry'</a> below.)</p><p class="headingAnchor" id="H1657032949"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Diagnostic criteria for MBL are [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Monoclonal population of B cells &lt;5000 cells/microL (&lt;5 x 10<sup>9</sup>/L) that persists for ≥3 months, as defined below. (See <a class="local">'B cell clonality'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No systemic features of a lymphoproliferative disorder (eg, no lymphadenopathy, hepatosplenomegaly, cytopenias, fever, weight loss, or sweats), autoimmune disorder, or infectious disease, as discussed above. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p>MBL should be categorized on the basis of immunophenotype and the size of the population of the B cell clone, as described below. (See <a class="local">'Classification and prognosis'</a> below.)</p><p class="headingAnchor" id="H2923828217"><span class="h2">B cell clonality</span><span class="headingEndMark"> — </span>Documentation of B cell clonality is required to diagnose MBL. For most patients, flow cytometry is the preferred method.</p><p class="headingAnchor" id="H1298418352"><span class="h3">Flow cytometry</span><span class="headingEndMark"> — </span>Multiparameter flow cytometry is used to document clonality, quantitate the size of the clonal population, and categorize the immunophenotype of MBL.</p><p>Flow cytometry analysis should at a minimum evaluate all of the following antigens:</p><p class="bulletIndent1"><span class="glyph">●</span>B cell: CD19, CD20, and CD23</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>T cell: CD3, CD5</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Surface immunoglobulin (sIg) kappa and lambda light chains</p><p></p><p class="headingAnchor" id="H3898914058"><span class="h4">Immunophenotype</span><span class="headingEndMark"> — </span>MBL should be categorized as one of the following on the basis of the immunophenotype  (<a class="graphic graphic_table graphicRef118411" href="/d/graphic/118411.html" rel="external">table 1</a>) (see <a class="local">'Classification and prognosis'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic lymphocytic leukemia (CLL)-like MBL </strong>– CD5+, CD19+, CD23 positive or negative, light chain restriction (ie, either kappa or lambda), sIg dim or negative (see <a class="local">'CLL-like MBL'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atypical CLL type MBL </strong>– CD5+, CD19+, CD20 moderate or bright, sIg moderate or bright, CD23 positive or negative (see <a class="local">'Atypical MBL'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Non-CLL type MBL </strong>– CD5 negative or dim, CD19+, CD20+, sIg moderate to bright (see <a class="local">'Non-CLL type MBL'</a> below)</p><p></p><p>Detection of either atypical CLL-type or non-CLL type MBL phenotype requires further evaluation for lymphoma or other lymphoproliferative disorder, as described separately. (See <a class="local">'B cell NHL'</a> below.)</p><p class="headingAnchor" id="H951215056"><span class="h4">Clone size</span><span class="headingEndMark"> — </span>Flow cytometry is used to measure the size of the B cell clonal population. There is a bimodal distribution of patients with MBL, and patients with CLL-like MBL can be characterized as either high-count MBL (&gt;2000/microL) or low-count MBL (&lt;50/microL); it is somewhat unusual to detect a clonal B cell count between 50 and 2000/microL. High-count and low-count MBL differ in regard to clinical setting, natural history, and prognosis, as described below. (See <a class="local">'High-count MBL'</a> below and <a class="local">'Low-count MBL'</a> below.)</p><p class="headingAnchor" id="H2361770682"><span class="h4">Sensitivity</span><span class="headingEndMark"> — </span>Sensitivity of flow cytometry to detect clonal B cells increases with the use of more antibodies (ie, colors) and greater numbers of cells analyzed. This is illustrated by reports of MBL prevalence in individuals ≥40 years old using increasingly sensitive flow cytometry techniques:</p><p class="bulletIndent1"><span class="glyph">●</span>3.5 percent with four-color flow cytometry evaluating 200,000 cells [<a href="#rid7">7,20</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>6.7 percent with five-color flow cytometry evaluating 500,000 cells [<a href="#rid8">8</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>12 percent with eight-color flow cytometry evaluating 5 million cells [<a href="#rid9">9</a>]</p><p></p><p class="headingAnchor" id="H2934079518"><span class="h3">Molecular characterization</span><span class="headingEndMark"> — </span>PCR (polymerase chain reaction) for immunoglobulin heavy chain (<em>IGHV</em>) rearrangement or other DNA-based assays can demonstrate B cell clonality. Occasionally, molecular analysis of blood or bone marrow (eg, for lymphoma or leukemia) will lead to detection of a B cell clone and the diagnosis of MBL. However, DNA-based assays do not identify the immunophenotypic category of MBL nor the size of the clonal population, which require flow cytometry, as described above. (See <a class="local">'Flow cytometry'</a> above.)</p><p>DNA-based assays are not required to make the diagnosis of MBL, but can be useful for special circumstances:</p><p class="bulletIndent1"><span class="glyph">●</span>Confirmation of a small clone of B cells by <em>IGHV</em> PCR on separated B cells in cases of low-count MBL</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Detection of <em>IGHV</em> gene somatic hypermutation may have prognostic value in high-count MBL, as it does with CLL (see  <a class="medical medical_review" href="/d/html/4489.html" rel="external">"Staging and prognosis of chronic lymphocytic leukemia", section on 'IGHV mutation status, ZAP-70, and CD38'</a>)</p><p></p><p class="headingAnchor" id="H2295319506"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis is influenced by whether or not there is lymphocytosis (ie, &gt;4000 lymphocytes/microL) or other clinical findings (eg, adenopathy, organomegaly, cytopenias, constitutional symptoms), the immunophenotype, and the size of the B cell clonal population.</p><p>In the presence of lymphocytosis, the differential diagnosis includes reactive causes (eg, infections, inflammatory states) and various lymphoproliferative disorders, as described separately. (See  <a class="medical medical_review" href="/d/html/104124.html" rel="external">"Approach to the adult with lymphocytosis or lymphocytopenia"</a>.)</p><p class="headingAnchor" id="H2656256546"><span class="h2">Infections</span><span class="headingEndMark"> — </span>Infections can cause lymphocytosis that generally resolves within weeks and may be associated with lymphadenopathy or organomegaly. Atypical lymphocytes  (<a class="graphic graphic_picture graphicRef55986" href="/d/graphic/55986.html" rel="external">picture 1</a>) may be seen on the blood smear, and the lymphocytosis is polyclonal. In contrast, MBL is a clonal disorder that persists for ≥3 months and has no associated lymphadenopathy or organomegaly. Diagnosis of infectious causes of lymphocytosis is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/104124.html" rel="external">"Approach to the adult with lymphocytosis or lymphocytopenia", section on 'Infectious causes'</a>.)</p><p class="headingAnchor" id="H1402098875"><span class="h2">CLL/SLL</span><span class="headingEndMark"> — </span>The diagnosis of chronic lymphocytic leukemia (CLL) requires peripheral blood B lymphocytosis ≥5000/microL, a characteristic immunophenotype (ie, CD5+, CD19+, dim or absent surface immunoglobulin [sIg], dim CD20), and may be associated with lymphadenopathy, organomegaly, and/or cytopenias [<a href="#rid21">21</a>].</p><p>Malignant cells of the related disorder, small lymphocytic lymphoma (SLL), are immunophenotypically similar, but the clinical presentation is dominated by lymphadenopathy or organomegaly, and the peripheral blood has &lt;5000 B lymphocytes/microL. Clinical features of CLL/SLL are discussed separately. (See  <a class="medical medical_review" href="/d/html/4513.html" rel="external">"Clinical features and diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma"</a>.)</p><p>Although the immunophenotype of CLL/SLL lymphocytes is indistinguishable from that of MBL, the latter is distinguished by the size of the population of the malignant clone (ie, &lt;5000/microL) and the absence of lymphadenopathy, organomegaly, and cytopenias. Detection of marrow infiltration by clonal B cells alone does not change the diagnosis from MBL to CLL/SLL. (See <a class="local">'Incidental marrow/tissue involvement'</a> below.)</p><p class="headingAnchor" id="H3321448310"><span class="h2">B cell NHL</span><span class="headingEndMark"> — </span>B cell non-Hodgkin lymphomas (NHL) are associated with clonal B cells and lymphadenopathy, organomegaly, cytopenias, and/or other tissue infiltration. B cell NHL may or may not be associated with circulating CD19+ B lymphocytes; in some cases, circulating cells may also be CD5+. However, MBL is excluded by a B cell count &gt;5000/microL and/or the presence of lymphadenopathy or organomegaly.</p><p>The B cell immunophenotype  (<a class="graphic graphic_table graphicRef118411" href="/d/graphic/118411.html" rel="external">table 1</a>) and other characteristics determine the specific categories of NHL in the differential diagnosis, which may include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mantle cell lymphoma</strong> <strong>(MCL) </strong>– Circulating lymphocytes in MCL are generally small and often have irregular or cleaved nuclei. MCL cells may be CD5+, CD19+, and CD20+, but are generally negative for CD23. MCL cells typically stain strongly for cyclin D1, CD20, and sIg, and usually have the characteristic t(11;14) chromosomal abnormality and/or <em>CCND1</em> rearrangement. (See  <a class="medical medical_review" href="/d/html/4702.html" rel="external">"Mantle cell lymphoma: Epidemiology, pathobiology, clinical manifestations, diagnosis, and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Marginal zone lymphoma (MZL) </strong>– MZL can present with lymphocytosis and is associated with lymphadenopathy, splenomegaly, cytopenias, and/or infiltration of other organs. Circulating B cells of MZL may have small surface "villous" projections  (<a class="graphic graphic_picture graphicRef59065" href="/d/graphic/59065.html" rel="external">picture 2</a>), and they express CD19, CD20, sIg, and CD23; some cases of MZL also express CD5. Although some cases of MBL have the same immunophenotype (eg, atypical MBL, non-CLL type MBL), a B cell clone &gt;5000/microL, lymphadenopathy, cytopenias, or organomegaly excludes the diagnosis of MBL. (See  <a class="medical medical_review" href="/d/html/4731.html" rel="external">"Splenic marginal zone lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Waldenström macroglobulinemia (WM) </strong>– WM and its lymphomatous counterpart, lymphoplasmacytic lymphoma (LPL),<strong> </strong>produce a prominent monoclonal immunoglobulin M (IgM) protein and may be associated with circulating B lymphoid cells (often with lymphoplasmacytic morphology); in a minority of cases WM/LPL cells are CD5+. WM/LPL can be distinguished from MBL by the presence of a monoclonal protein on serum protein electrophoresis, strong staining for surface IgM and CD20, and cytoplasmic immunoglobulin. (See  <a class="medical medical_review" href="/d/html/6657.html" rel="external">"Epidemiology, pathogenesis, clinical manifestations, and diagnosis of Waldenström macroglobulinemia"</a>.)</p><p></p><p class="headingAnchor" id="H3690080795"><span class="h2">Acute lymphoblastic leukemia (ALL)</span><span class="headingEndMark"> — </span>Patients with ALL typically present with variable levels of circulating lymphoblasts, cytopenias, constitutional symptoms, and may have a mediastinal mass or lymphadenopathy. Lymphoblasts may be small with scant cytoplasm or larger with moderate amounts of cytoplasm. Cells are positive for terminal deoxytransferase (TdT), and depending on the lineage, express either B cell antigens (eg, CD19, CD20, and CD10) or T cell antigens (eg, CD3, CD7).</p><p>MBL is distinguished by immunophenotype; the absence of lymphoblasts, adenopathy, organomegaly, cytopenias, and constitutional symptoms; and TdT negativity. (See  <a class="medical medical_review" href="/d/html/4686.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of B cell acute lymphoblastic leukemia/lymphoma"</a> and  <a class="medical medical_review" href="/d/html/15773.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma"</a>.)</p><p class="headingAnchor" id="H544647815"><span class="h2">Large granular lymphocyte (LGL) leukemia</span><span class="headingEndMark"> — </span>Lymphocytosis in LGL leukemia is typically modest, but LGLs  (<a class="graphic graphic_picture graphicRef69027" href="/d/graphic/69027.html" rel="external">picture 3</a>) are large, with abundant cytoplasm containing fine or coarse azurophilic granules and a reniform or round nucleus. Patients often present with cytopenias, splenomegaly, and constitutional symptoms. T cell LGL leukemias are CD3+, CD57+, and express the alpha/beta T cell receptor (TCR). NK cell LGL leukemias are CD56+ but CD3 negative. MBL is distinguished by immunophenotype and absence of constitutional symptoms and splenomegaly. (See  <a class="medical medical_review" href="/d/html/16360.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of T cell large granular lymphocyte leukemia"</a> and  <a class="medical medical_review" href="/d/html/4538.html" rel="external">"Natural killer (NK) cell large granular lymphocyte leukemia"</a>.)</p><p class="headingAnchor" id="H1832259353"><span class="h2">Sézary syndrome (SS)</span><span class="headingEndMark"> — </span>The peripheral blood of patients with SS is characterized by a large number of atypical mononuclear cells with moderately to highly grooved (ie, cerebriform) nuclei  (<a class="graphic graphic_picture graphicRef70592" href="/d/graphic/70592.html" rel="external">picture 4</a>), and patients commonly present with erythroderma and generalized lymphadenopathy. The circulating lymphocytes are CD4+, and skin biopsy usually reveals atypical lymphocytes in a sparse dermal infiltrate. MBL is distinguished by the absence of the characteristic SS morphology, immunophenotype, and skin involvement and organomegaly. (See  <a class="medical medical_review" href="/d/html/4694.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified"</a>.)</p><p class="headingAnchor" id="H1342353975"><span class="h1">CLASSIFICATION AND PROGNOSIS</span><span class="headingEndMark"> — </span>All cases of MBL should be categorized on the basis of immunophenotype. The various categories of MBL are associated with distinct natural history, prognosis, and management, as described in the sections below.</p><p class="headingAnchor" id="H1771051930"><span class="h2">CLL-like MBL</span><span class="headingEndMark"> — </span>Chronic lymphocytic leukemia (CLL)-like MBL is the most common category and accounts for about three-quarters of all cases of MBL [<a href="#rid7">7,12,20,22</a>].</p><p>CLL-like MBL is so-named because of its close immunophenotypic resemblance to CLL  (<a class="graphic graphic_table graphicRef118411" href="/d/graphic/118411.html" rel="external">table 1</a>). The clonal cells of CLL-like MBL are CD5+, CD19+, have dim expression of CD20, and are typically CD23+. They demonstrate light chain restriction (ie, either kappa or lambda) and express dim surface immunoglobulin (sIg) or no sIg (in one-quarter of cases) [<a href="#rid7">7,22</a>].</p><p>More than one clone of B cells may be detected [<a href="#rid8">8,9,23,24</a>].</p><p class="headingAnchor" id="H2549105350"><span class="h3">High- versus low-count CLL-like MBL</span><span class="headingEndMark"> — </span>Based on the size of the malignant clone, there is a bimodal distribution of patients with CLL-like MBL, and cases can be classified as either high-count MBL (&gt;2000/microL) or low-count MBL (&lt;50/microL), which differ in regard to clinical setting, natural history, and prognosis [<a href="#rid22">22</a>].</p><p>It is somewhat unusual to detect a clonal B cell count between 50 and 2000/microL, but we manage such patients as high-count MBL.</p><p class="headingAnchor" id="H4129409392"><span class="h3">High-count MBL</span><span class="headingEndMark"> — </span>High-count CLL-like MBL (&gt;2000 clonal B lymphocytes/microL) is the most common category of MBL that is identified in the course of evaluation for lymphocytosis or other clinical findings [<a href="#rid25">25</a>]. In many respects, it resembles an indolent form of early stage CLL. Compared with low-count MBL, patients with high-count MBL have a higher risk of infection, progression to CLL, and development of a nonhematologic cancer.</p><p>Clonal B cells constitute the predominant lymphocyte population in high-count MBL; the median clonal B cell count is 2939/microL [<a href="#rid22">22</a>]. By definition, there is no associated lymphadenopathy, organomegaly, cytopenias, or other findings of a lymphoma or other underlying disease. (See <a class="local">'Diagnosis'</a> above.)</p><p>High-count MBL has biologic features that are similar to early stage CLL, and its natural history appears to dovetail into the CLL clinical disease spectrum [<a href="#rid8">8,23,26,27</a>]. Indeed, the cutoff of 5000 B lymphocytes/microL for distinguishing clinical MBL from CLL is somewhat arbitrary, lacking a definitive clinical and/or biological justification [<a href="#rid1">1,4</a>]. High-count MBL and CLL have similar chromosomal abnormalities (eg, loss of 13q) and frequency of mutated immunoglobulin heavy chain (<em>IGHV</em>), but in MBL there is a higher proportion of patients with favorable prognostic markers (eg, about 75 to 90 percent of MBL patients have mutated <em>IGHV</em>, whereas only about 50 percent of CLL patients do). MBL patients also tend to have fewer somatic mutations (eg, <em>NOTCH1, SF3B1, ATM, TP53</em>) than CLL patients [<a href="#rid23">23,28-31</a>]. Some patients have clonal lymphocyte counts that oscillate between MBL and CLL (ie, above or below 5000/microL) for years. (See  <a class="medical medical_review" href="/d/html/4513.html" rel="external">"Clinical features and diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma"</a>.)</p><p>Although the overall survival of patients with high-count MBL does not differ from that of the general population [<a href="#rid32">32-34</a>], there is an association with the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infections</strong> – Infections are the greatest risk to health. In a case control study, MBL was associated with a threefold increased risk of hospitalization due to infection [<a href="#rid35">35</a>]. The risk of serious infection for a patient with high-count MBL is four times higher than the rate of progression to CLL. The deleterious effect of MBL on immunity is illustrated by a study of nearly 700 patients with MBL in whom the risk for infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was not higher than that of an age-matched population, but there was a higher risk of severe infection and hospitalization [<a href="#rid36">36</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Progression </strong>– The estimated rate of progression from high-count MBL to CLL is 1 to 2 percent per year, and there is no apparent plateau in incidence [<a href="#rid25">25,26</a>]. In a single-institution study that included 415 individuals with MBL, median overall survival (OS) was 17.9 years (longer than that of age- and sex-matched general population) and the time to first therapy (TTFT) for CLL was 2.9 percent/year [<a href="#rid37">37</a>]. Approximately 60 percent of these patients had a low-risk CLL-IPI score, 28 percent had an intermediate-risk score, and 10 percent had a high/very high-risk score; both TTFT and OS were inversely correlated with the CLL-IPI score. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonhematologic cancers</strong> – There is an increased risk of developing a nonhematologic cancer. Compared with controls, with nearly five years of follow-up, patients with high-count MBL had twice the rate of developing breast, lung, or gastrointestinal cancers [<a href="#rid38">38</a>].</p><p></p><p>Follow-up and monitoring of patients with high-count MBL is described below. (See <a class="local">'Monitoring'</a> below.)</p><p class="headingAnchor" id="H645707073"><span class="h3">Low-count MBL</span><span class="headingEndMark"> — </span>Low-count CLL-like MBL (&lt;50/microL) is rarely associated with lymphocytosis or other findings but affected individuals may have an increased risk for serious infections and progression to CLL. At present, it is uncertain if low-count MBL is part of a spectrum that extends to high-count MBL and CLL or if it is simply an epiphenomenon associated with aging. </p><p>Because individuals with low-count MBL generally have normal blood counts, no lymphocytosis, and no other clinical findings, it is usually detected in population-based surveys. The median size of the malignant clone is 1 clonal B lymphocyte/microL, and 95 percent of affected individuals have &lt;56/microL [<a href="#rid22">22</a>]. </p><p>Compared with the general population, low-count MBL may be associated with increased risk for serious infections and progression to CLL, but these findings should be validated with independent reports.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infections</strong> – One study identified 106 individuals with low-count MBL from a biobank of asymptomatic adults ≥40 years old and compared their outcomes with 865 controls from the same biobank who did not have MBL; the groups were well-matched with regard to demographics, medical history, baseline blood counts, and comorbid illnesses [<a href="#rid10">10</a>]. Compared with the controls, patients with MBL had an increased eight-year cumulative incidence of infections (23 versus 11 percent, respectively), pneumonia (9 versus 2 percent), and sepsis (9 versus 2 percent), but there was no difference in overall survival. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Progression </strong>– In a study of 310 families that had ≥2 family members with CLL, highly-sensitive flow cytometry identified low-count MBL in 13 percent (139 individuals among 1045 relatives); individuals with low-count MBL were estimated to have a 1.1 percent/year rate of progression from low-count MBL to CLL [<a href="#rid13">13</a>]. In addition, among 264 relatives who had no MBL at baseline, 60 subsequently developed MBL (58 with low-count MBL and 2 with high-count MBL) after a median of six years of follow-up. In a prospective study of 76 individuals with low-count CLL-like MBL, with median follow-up of nearly three years, the B cell clone persisted in 90 percent, but no patient progressed to CLL or other lymphoid malignancy [<a href="#rid26">26</a>].</p><p></p><p>It is presently uncertain whether low-count MBL is part of a spectrum that extends to high-count MBL and CLL. Low-count MBL differs from CLL and high-count MBL in regard to immunoglobulin repertoire, cytogenetic abnormalities, and molecular mutations [<a href="#rid8">8,23,26,30,39</a>]. Some investigators have hypothesized that low-count MBL may reflect an epiphenomenon of immunosenescence associated with aging, because highly sensitive assays can detect small B cell clones in the majority of older patients [<a href="#rid26">26,27,40</a>]. (See <a class="local">'Flow cytometry'</a> above.)</p><p>Follow-up and monitoring of patients with low-count MBL is described below. (See <a class="local">'Monitoring low-count MBL'</a> below.)</p><p class="headingAnchor" id="H137464002"><span class="h2">Atypical MBL</span><span class="headingEndMark"> — </span>In atypical CLL-like MBL, a monoclonal B cell clone &lt;5000/microL expresses CD5 and CD19, but it differs from typical CLL because of bright expression of CD20 and moderate or bright sIg expression; CD23 may be positive or negative  (<a class="graphic graphic_table graphicRef118411" href="/d/graphic/118411.html" rel="external">table 1</a>). Although this immunophenotype is compatible with certain B cell non-Hodgkin lymphomas (especially mantle cell lymphoma), by definition, it is not accompanied by lymphadenopathy, organomegaly, cytopenias, or other findings of a lymphoma. (See <a class="local">'Diagnosis'</a> above.)</p><p>Atypical CLL-like MBL must be distinguished from B cell lymphomas by imaging, cytogenetics, molecular studies, and/or other tests. Lymphadenopathy, splenomegaly, and other organ involvement should be excluded by computerized tomography (CT) of chest, abdomen, and pelvis. Differential diagnosis and tests to exclude B cell non-Hodgkin lymphomas are discussed above. (See <a class="local">'B cell NHL'</a> above.)</p><p>Compared with CLL-like MBL, atypical MBL is much less common and its biology and natural history are less well described [<a href="#rid6">6,7,9,20</a>].</p><p>Monitoring of atypical MBL is described below. (See <a class="local">'Monitoring high-count, atypical, and non-CLL type MBL'</a> below.)</p><p class="headingAnchor" id="H3391370007"><span class="h2">Non-CLL type MBL</span><span class="headingEndMark"> — </span>Non-CLL type MBL is characterized by &lt;5000/microL monoclonal B cells that are CD5 negative or dim, but express CD19, CD20, and moderate to bright sIg; by definition, there is no lymphadenopathy, organomegaly, cytopenias, or other findings of a lymphoma. The immunophenotype is consistent with certain B cell non-Hodgkin lymphomas and the distinction of non-CLL type MBL from mantle cell lymphoma, marginal zone lymphoma, and Waldenström macroglobulinemia by cytogenetics, molecular studies, and/or other tests is discussed above. (See <a class="local">'B cell NHL'</a> above.)</p><p>Non-CLL type MBL represents less than one-fifth of cases of MBL. The prevalence of non-CLL type MBL is estimated at 1 to 2 percent in the general population, and the incidence rises with increasing age [<a href="#rid6">6,20,25</a>]. Some cases of non-CLL type MBL may be transient and self-limited [<a href="#rid26">26</a>]. In one report, 4 of 13 cases of atypical MBL were biclonal [<a href="#rid6">6</a>].</p><p>A study of 23 patients with non-CLL type MBL reported lymphocytosis in 16 patients, and bone marrow involvement in all patients [<a href="#rid5">5</a>]. In another study, four of seven patients had cytogenetic abnormalities (eg, 7q abnormalities, isochromosome 17 with loss of <em>TP53</em>) [<a href="#rid41">41</a>].</p><p>The natural history of non-CLL type MBL is not well characterized. This disorder may be related to splenic marginal zone lymphoma, but reports of outcomes are not consistent across various studies. In a study that followed seven patients for 4 to 16 years, there was no evidence of progression to overt lymphoma despite the persistence of lymphocytosis [<a href="#rid41">41</a>]. However, in another study, as many as 17 percent eventually developed splenomegaly, suggesting that this disorder may be related to splenic marginal zone lymphoma [<a href="#rid42">42</a>].</p><p>Monitoring of non-CLL type MBL is described below. (See <a class="local">'Monitoring high-count, atypical, and non-CLL type MBL'</a> below.)</p><p class="headingAnchor" id="H3838253051"><span class="h1">CLINICAL DILEMMAS</span><span class="headingEndMark"> — </span>Management dilemmas may arise in some settings of MBL.</p><p class="headingAnchor" id="H2608834607"><span class="h2">Incidental marrow/tissue involvement</span><span class="headingEndMark"> — </span>The serendipitous finding of clonal B cell infiltration of bone marrow, lymph nodes, or other tissues may lead to the diagnosis of MBL. Such patients should be evaluated by computerized tomography (CT) scans to exclude lymphoma. Detection of such B cell infiltration in the setting of MBL (ie, &lt;5000 B cells/microL in peripheral blood with no lymphadenopathy, organomegaly, or cytopenias) does not alter the diagnosis or prognosis of MBL.</p><p>As examples, bone marrow examination for staging of a hematologic malignancy (eg, leukemia, lymphoma) or for other reasons (eg, immune thrombocytopenia) may unexpectedly reveal infiltration by chronic lymphocytic leukemia (CLL)-like cells. The degree of infiltration is variable, but one study reported a median of 20 percent bone marrow involvement by MBL cells [<a href="#rid43">43</a>]. The degree of bone marrow involvement by MBL cells does not predict the likelihood of clinical progression of MBL [<a href="#rid44">44,45</a>].</p><p>Similarly, liver biopsy or staging of a cancer (eg, lymph node biopsy for prostate cancer or breast cancer) may unexpectedly reveal infiltration by CLL-like cells. Clonal MBL cells have been detected in 2 percent of liver biopsy specimens and up to 0.4 percent of prostate tissues at the time of prostatectomy, but progression to CLL/SLL is only rarely seen [<a href="#rid46">46-50</a>]. Lymph node infiltration by CLL-type cells without proliferation centers and no evidence of organomegaly or lymphadenopathy (ie, none &gt;1.5 cm on CT scans) may constitute a nodal equivalent of MBL (rather than small lymphocytic lymphoma [SLL]) [<a href="#rid51">51</a>].</p><p>We manage the unexpected/serendipitous finding of MBL cells in bone marrow or other tissue based on the immunophenotype, clone size, and classification. (See <a class="local">'Classification and prognosis'</a> above.)</p><p>Monitoring of MBL is described below. (See <a class="local">'Monitoring'</a> below.)</p><p class="headingAnchor" id="H3431909405"><span class="h2">Stem cell/blood donation</span><span class="headingEndMark"> — </span>The presence of high-count CLL-like MBL may affect the patient's candidacy as a stem cell donor for allogeneic hematopoietic cell transplantation (HCT), but it does not affect the ability to donate blood for transfusion.</p><p>MBL is more frequent in first-degree relatives of patients with both familial and sporadic CLL, and transfer of MBL from donor to recipient following allogeneic HCT has been described [<a href="#rid52">52-54</a>]. Consideration of patients with MBL as potential stem cell donors is discussed separately. (See  <a class="medical medical_review" href="/d/html/3535.html" rel="external">"Donor selection for hematopoietic cell transplantation", section on 'Effect of donor characteristics'</a> and  <a class="medical medical_review" href="/d/html/96033.html" rel="external">"Evaluation of the hematopoietic cell transplantation donor", section on 'Candidacy for donation'</a>.)</p><p>There are no reports of transmission of MBL via blood transfusion. We suggest <strong>not</strong> screening blood donors for MBL, even though the prevalence of MBL in voluntary blood donors has been reported as high as 7 percent [<a href="#rid3">3,55</a>]. Some epidemiologic studies have suggested that blood transfusions may be associated with an increased risk of developing CLL [<a href="#rid56">56,57</a>], but this has been disputed because some cases may have been related to transfusion-associated hepatitis C virus infection [<a href="#rid58">58</a>].</p><p class="headingAnchor" id="H3761319449"><span class="h1">MONITORING</span><span class="headingEndMark"> — </span>Monitoring of individuals with MBL is guided by the immunophenotypic category and the size of the B cell clonal population. (See <a class="local">'Classification and prognosis'</a> above.)</p><p class="headingAnchor" id="H1207996050"><span class="h2">Monitoring high-count, atypical, and non-CLL type MBL</span><span class="headingEndMark"> — </span>Individuals with high-count CLL-like MBL, atypical MBL, and non-CLL type MBL should be monitored clinically for progression to chronic lymphocytic leukemia (CLL) or other lymphoproliferative disorder (eg, progression of non-CLL type MBL to marginal zone lymphoma). In the absence of clinical progression, there is no need for routine imaging studies, bone marrow examination, or repeat flow cytometry.</p><p>We obtain interval history, physical examination, and complete blood count (CBC) with differential count twice a year for the first two years. If the patient is clinically stable and the lymphocyte count is relatively unchanged, we extend the interval to annual visits. We inform the patient of the diagnosis and discuss the small but cumulative risk of progression to CLL. (See <a class="local">'High-count MBL'</a> above.)</p><p>Patients should report lymphadenopathy or B symptoms (eg, fever, sweats, weight loss) to their clinician. If such findings develop, or the lymphocyte count rises to &gt;10,000/microL on two consecutive visits, we typically repeat flow cytometry to evaluate immunophenotypic shift in association with progression to CLL. Management of early stage CLL is described separately. (See  <a class="medical medical_review" href="/d/html/4513.html" rel="external">"Clinical features and diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma"</a>.)</p><p>Routine imaging is not performed because detection of subclinical findings does not alter prognosis in MBL. In one study, 29 of 62 patients (42 percent) had adenopathy detected on CT scanning, but after a median of 35 months, only 2 of 29 progressed on CT (7 percent), which is not different from cases of MBL without lymphadenopathy (9 percent; 3 of 33 patients) [<a href="#rid59">59</a>].</p><p class="headingAnchor" id="H1053972243"><span class="h2">Monitoring low-count MBL</span><span class="headingEndMark"> — </span>Low-count CLL-like MBL has a low risk of progression to CLL, but there may be an increased risk for serious infections, as discussed above. (See <a class="local">'Low-count MBL'</a> above.)</p><p>There is no consensus regarding optimal management of low-count MBL. Follow-up should be individualized and may be influenced by concerns on the part the clinician and/or affected individual. We favor informing the patient of the diagnosis and advising about a possible increased risk for serious infections, recognizing that this potential risk is based on a single, unconfirmed report [<a href="#rid10">10</a>]. Other experts suggest that because the prognosis is excellent and there is no increased risk for transformation to CLL, it is not necessary to inform the patient of the diagnosis. </p><p class="headingAnchor" id="H3013631683"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Description</strong> – Monoclonal B cell lymphocytosis (MBL) refers to a monoclonal population of B lymphocytes &lt;5000 cells/microL, without lymphadenopathy, organomegaly, cytopenias, or other features of a B cell lymphoproliferative disorder. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – Includes history and physical examination, complete blood count (CBC) with differential count, review of blood smear, and documentation of a B cell clone. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clonality</strong> – Multiparameter flow cytometry is used to define B cell clonality, define the immunophenotype, and measure the size of the clonal population. (See <a class="local">'Flow cytometry'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – Includes reactive processes (eg, infections, inflammatory conditions) and B cell malignancies but the differential diagnosis varies with level of lymphocytosis, clinical findings (eg, adenopathy, organomegaly, cytopenias, constitutional symptoms), immunophenotype, and clone size. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>CLL-like MBL</strong> – Immunophenotype resembles that of chronic lymphocytic leukemia (CLL; ie, CD5+, CD19+, usually CD23+, dim/absent CD20, low/absent surface immunoglobulin [sIg]). CLL-like MBL accounts for three-quarters of MBL cases. (See <a class="local">'CLL-like MBL'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Subcategorized</strong> – Based on clone size:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>High-count MBL</strong> &gt;2000 clonal B lymphocytes/microL (see <a class="local">'High-count MBL'</a> above)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Low-count MBL </strong>&lt;50/microL (see <a class="local">'Low-count MBL'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Atypical MBL</strong> – CD5+, CD19+, moderate/bright CD20, sIg expression. All cases should be evaluated for an underlying lymphoma. (See <a class="local">'Atypical MBL'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Non-CLL type MBL</strong> – Resembles immunophenotype of marginal zone lymphoma (ie, CD5 negative/dim, CD19+, CD20+ bright, moderate/bright sIg expression) and distinct from that of CLL. (See <a class="local">'Non-CLL type MBL'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incidental MBL</strong> – Clonal B cell infiltration (bone marrow, lymph node, or other tissue) is found while evaluating other disorders. The patient should be evaluated for a lymphoma, but the finding of incidental MBL does not alter prognosis of the lymphoma. (See <a class="local">'Incidental marrow/tissue involvement'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blood/transplant donation</strong> – High-count, CLL-like MBL does not affect suitability as a donor for blood transfusion, but it may affect eligibility as a stem cell donor for allogeneic hematopoietic cell transplantation. (See <a class="local">'Stem cell/blood donation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – Guided by the immunophenotype and size of the clonal population:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>High-count, CLL type MBL, atypical MBL, and non-CLL type MBL</strong> – Follow up periodically with history, physical examination, and blood counts. Flow cytometry or imaging is performed <strong>only</strong> for a sustained rise in lymphocyte count and/or symptoms suggestive of progression to CLL or other lymphoma. (See <a class="local">'Monitoring high-count, atypical, and non-CLL type MBL'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Low-count MBL.</strong> (See <a class="local">'Monitoring low-count MBL'</a> above.)</p><p></p><p class="headingAnchor" id="H4209969476"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editors of UpToDate acknowledge the contributions of Stanley L Schrier, MD as Section Editor on this topic, his tenure as the founding Editor-in-Chief for UpToDate in Hematology, and his dedicated and longstanding involvement with the UpToDate program.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Marti GE, Rawstron AC, Ghia P, et al. Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol 2005; 130:325.</a></li><li class="breakAll">WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), International Agency for Research on Cancer (IARC), Lyon 2017.</li><li><a class="nounderline abstract_t">Shim YK, Rachel JM, Ghia P, et al. Monoclonal B-cell lymphocytosis in healthy blood donors: an unexpectedly common finding. Blood 2014; 123:1319.</a></li><li><a class="nounderline abstract_t">Shanafelt TD, Ghia P, Lanasa MC, et al. Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management. Leukemia 2010; 24:512.</a></li><li><a class="nounderline abstract_t">Kalpadakis C, Pangalis GA, Sachanas S, et al. New insights into monoclonal B-cell lymphocytosis. Biomed Res Int 2014; 2014:258917.</a></li><li><a class="nounderline abstract_t">Nieto WG, Teodosio C, López A, et al. Non-CLL-like monoclonal B-cell lymphocytosis in the general population: prevalence and phenotypic/genetic characteristics. Cytometry B Clin Cytom 2010; 78 Suppl 1:S24.</a></li><li><a class="nounderline abstract_t">Rawstron AC, Green MJ, Kuzmicki A, et al. Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood 2002; 100:635.</a></li><li><a class="nounderline abstract_t">Dagklis A, Fazi C, Sala C, et al. The immunoglobulin gene repertoire of low-count chronic lymphocytic leukemia (CLL)-like monoclonal B lymphocytosis is different from CLL: diagnostic implications for clinical monitoring. Blood 2009; 114:26.</a></li><li><a class="nounderline abstract_t">Nieto WG, Almeida J, Romero A, et al. Increased frequency (12%) of circulating chronic lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach. Blood 2009; 114:33.</a></li><li><a class="nounderline abstract_t">Shanafelt TD, Kay NE, Parikh SA, et al. Risk of serious infection among individuals with and without low count monoclonal B-cell lymphocytosis (MBL). Leukemia 2021; 35:239.</a></li><li><a class="nounderline abstract_t">Marti GE, Carter P, Abbasi F, et al. B-cell monoclonal lymphocytosis and B-cell abnormalities in the setting of familial B-cell chronic lymphocytic leukemia. Cytometry B Clin Cytom 2003; 52:1.</a></li><li><a class="nounderline abstract_t">Rawstron AC, Yuille MR, Fuller J, et al. Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion. Blood 2002; 100:2289.</a></li><li><a class="nounderline abstract_t">Slager SL, Lanasa MC, Marti GE, et al. Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families. Blood 2021; 137:2046.</a></li><li><a class="nounderline abstract_t">Matos DM, Ismael SJ, Scrideli CA, et al. Monoclonal B-cell lymphocytosis in first-degree relatives of patients with sporadic (non-familial) chronic lymphocytic leukaemia. Br J Haematol 2009; 147:339.</a></li><li><a class="nounderline abstract_t">Crowther-Swanepoel D, Corre T, Lloyd A, et al. Inherited genetic susceptibility to monoclonal B-cell lymphocytosis. Blood 2010; 116:5957.</a></li><li><a class="nounderline abstract_t">Kleinstern G, Camp NJ, Goldin LR, et al. Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood 2018; 131:2541.</a></li><li><a class="nounderline abstract_t">Anderson LA, Landgren O, Engels EA. Common community acquired infections and subsequent risk of chronic lymphocytic leukaemia. Br J Haematol 2009; 147:444.</a></li><li><a class="nounderline abstract_t">Casabonne D, Almeida J, Nieto WG, et al. Common infectious agents and monoclonal B-cell lymphocytosis: a cross-sectional epidemiological study among healthy adults. PLoS One 2012; 7:e52808.</a></li><li><a class="nounderline abstract_t">Anderson LA, Pfeiffer R, Warren JL, et al. Hematopoietic malignancies associated with viral and alcoholic hepatitis. Cancer Epidemiol Biomarkers Prev 2008; 17:3069.</a></li><li><a class="nounderline abstract_t">Ghia P, Prato G, Scielzo C, et al. Monoclonal CD5+ and CD5- B-lymphocyte expansions are frequent in the peripheral blood of the elderly. Blood 2004; 103:2337.</a></li><li><a class="nounderline abstract_t">Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 2018; 131:2745.</a></li><li><a class="nounderline abstract_t">Rawstron AC, Shanafelt T, Lanasa MC, et al. Different biology and clinical outcome according to the absolute numbers of clonal B-cells in monoclonal B-cell lymphocytosis (MBL). Cytometry B Clin Cytom 2010; 78 Suppl 1:S19.</a></li><li><a class="nounderline abstract_t">Henriques A, Rodríguez-Caballero A, Nieto WG, et al. Combined patterns of IGHV repertoire and cytogenetic/molecular alterations in monoclonal B lymphocytosis versus chronic lymphocytic leukemia. PLoS One 2013; 8:e67751.</a></li><li><a class="nounderline abstract_t">Lanasa MC, Allgood SD, Volkheimer AD, et al. Single-cell analysis reveals oligoclonality among 'low-count' monoclonal B-cell lymphocytosis. Leukemia 2010; 24:133.</a></li><li><a class="nounderline abstract_t">Rawstron AC, Bennett FL, O'Connor SJ, et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med 2008; 359:575.</a></li><li><a class="nounderline abstract_t">Fazi C, Scarfò L, Pecciarini L, et al. General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. Blood 2011; 118:6618.</a></li><li><a class="nounderline abstract_t">Vardi A, Dagklis A, Scarfò L, et al. Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL. Blood 2013; 121:4521.</a></li><li><a class="nounderline abstract_t">Kern W, Bacher U, Haferlach C, et al. Monoclonal B-cell lymphocytosis is closely related to chronic lymphocytic leukaemia and may be better classified as early-stage CLL. Br J Haematol 2012; 157:86.</a></li><li><a class="nounderline abstract_t">Puente XS, Beà S, Valdés-Mas R, et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature 2015; 526:519.</a></li><li><a class="nounderline abstract_t">Greco M, Capello D, Bruscaggin A, et al. Analysis of SF3B1 mutations in monoclonal B-cell lymphocytosis. Hematol Oncol 2013; 31:54.</a></li><li><a class="nounderline abstract_t">Foà R, Del Giudice I, Guarini A, et al. Clinical implications of the molecular genetics of chronic lymphocytic leukemia. Haematologica 2013; 98:675.</a></li><li><a class="nounderline abstract_t">Molica S, Mauro FR, Giannarelli D, et al. Differentiating chronic lymphocytic leukemia from monoclonal B-lymphocytosis according to clinical outcome: on behalf of the GIMEMA chronic lymphoproliferative diseases working group. Haematologica 2011; 96:277.</a></li><li><a class="nounderline abstract_t">Molica S, Levato D, Dattilo A. Natural history of early chronic lymphocytic leukemia. A single institution study with emphasis on the impact of disease-progression on overall survival. Haematologica 1999; 84:1094.</a></li><li><a class="nounderline abstract_t">Shanafelt TD, Kay NE, Rabe KG, et al. Survival of patients with clinically identified monoclonal B-cell lymphocytosis (MBL) relative to the age- and sex-matched general population. Leukemia 2012; 26:373.</a></li><li><a class="nounderline abstract_t">Moreira J, Rabe KG, Cerhan JR, et al. Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls. Leukemia 2013; 27:136.</a></li><li><a class="nounderline abstract_t">Parikh SA, Achenbach SJ, Rabe KG, et al. The risk of coronavirus disease 2019 (COVID-19) among individuals with monoclonal B cell lymphocytosis. Blood Cancer J 2022; 12:159.</a></li><li><a class="nounderline abstract_t">Parikh SA, Rabe KG, Kay NE, et al. The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL. Blood 2021; 138:149.</a></li><li><a class="nounderline abstract_t">Solomon BM, Chaffee KG, Moreira J, et al. Risk of non-hematologic cancer in individuals with high-count monoclonal B-cell lymphocytosis. Leukemia 2016; 30:331.</a></li><li><a class="nounderline abstract_t">Rasi S, Monti S, Spina V, et al. Analysis of NOTCH1 mutations in monoclonal B-cell lymphocytosis. Haematologica 2012; 97:153.</a></li><li><a class="nounderline abstract_t">Almeida J, Nieto WG, Teodosio C, et al. CLL-like B-lymphocytes are systematically present at very low numbers in peripheral blood of healthy adults. Leukemia 2011; 25:718.</a></li><li><a class="nounderline abstract_t">Amato D, Oscier DG, Davis Z, et al. Cytogenetic aberrations and immunoglobulin VH gene mutations in clinically benign CD5- monoclonal B-cell lymphocytosis. Am J Clin Pathol 2007; 128:333.</a></li><li><a class="nounderline abstract_t">Xochelli A, Kalpadakis C, Gardiner A, et al. Clonal B-cell lymphocytosis exhibiting immunophenotypic features consistent with a marginal-zone origin: is this a distinct entity? Blood 2014; 123:1199.</a></li><li><a class="nounderline abstract_t">Rossi D, Sozzi E, Puma A, et al. The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors. Br J Haematol 2009; 146:64.</a></li><li><a class="nounderline abstract_t">Oliveira AC, Fernández de Sevilla A, Domingo A, et al. Prospective study of prognostic factors in asymptomatic patients with B-cell chronic lymphocytic leukemia-like lymphocytosis: the cut-off of 11 × 10(9)/L monoclonal lymphocytes better identifies subgroups with different outcomes. Ann Hematol 2015; 94:627.</a></li><li><a class="nounderline abstract_t">Randen U, Tierens AM, Tjønnfjord GE, Delabie J. Bone marrow histology in monoclonal B-cell lymphocytosis shows various B-cell infiltration patterns. Am J Clin Pathol 2013; 139:390.</a></li><li><a class="nounderline abstract_t">Rawstron AC. Occult B-cell lymphoproliferative disorders. Histopathology 2011; 58:81.</a></li><li><a class="nounderline abstract_t">Winstanley AM, Sandison A, Bott SR, et al. Incidental findings in pelvic lymph nodes at radical prostatectomy. J Clin Pathol 2002; 55:623.</a></li><li><a class="nounderline abstract_t">Chu PG, Huang Q, Weiss LM. Incidental and concurrent malignant lymphomas discovered at the time of prostatectomy and prostate biopsy: a study of 29 cases. Am J Surg Pathol 2005; 29:693.</a></li><li><a class="nounderline abstract_t">Liu CL, Fan ST, Lo CM, et al. Hepatic resection for incidentaloma. J Gastrointest Surg 2004; 8:785.</a></li><li><a class="nounderline abstract_t">He H, Cheng L, Weiss LM, Chu PG. Clinical outcome of incidental pelvic node malignant B-cell lymphomas discovered at the time of radical prostatectomy. Leuk Lymphoma 2007; 48:1976.</a></li><li><a class="nounderline abstract_t">Gibson SE, Swerdlow SH, Ferry JA, et al. Reassessment of small lymphocytic lymphoma in the era of monoclonal B-cell lymphocytosis. Haematologica 2011; 96:1144.</a></li><li><a class="nounderline abstract_t">Perz JB, Ritgen M, Moos M, et al. Occurrence of donor-derived CLL 8 years after sibling donor SCT for CML. Bone Marrow Transplant 2008; 42:687.</a></li><li><a class="nounderline abstract_t">Hardy NM, Grady C, Pentz R, et al. Bioethical considerations of monoclonal B-cell lymphocytosis: donor transfer after haematopoietic stem cell transplantation. Br J Haematol 2007; 139:824.</a></li><li><a class="nounderline abstract_t">Ferrand C, Garnache-Ottou F, Collonge-Rame MA, et al. Systematic donor blood qualification by flow cytometry would have been able to avoid CLL-type MBL transmission after unrelated hematopoietic stem cell transplantation. Eur J Haematol 2012; 88:269.</a></li><li><a class="nounderline abstract_t">Rachel JM, Zucker ML, Fox CM, et al. Monoclonal B-cell lymphocytosis in blood donors. Br J Haematol 2007; 139:832.</a></li><li><a class="nounderline abstract_t">Brandt L, Brandt J, Olsson H, et al. Blood transfusion as a risk factor for non-Hodgkin lymphoma. Br J Cancer 1996; 73:1148.</a></li><li><a class="nounderline abstract_t">Cerhan JR, Wallace RB, Dick F, et al. Blood transfusions and risk of non-Hodgkin's lymphoma subtypes and chronic lymphocytic leukemia. Cancer Epidemiol Biomarkers Prev 2001; 10:361.</a></li><li><a class="nounderline abstract_t">Slager SL, Benavente Y, Blair A, et al. Medical history, lifestyle, family history, and occupational risk factors for chronic lymphocytic leukemia/small lymphocytic lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr 2014; 2014:41.</a></li><li><a class="nounderline abstract_t">Gentile M, Cutrona G, Fabris S, et al. Total body computed tomography scan in the initial work-up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter O-CLL1-GISL study. Am J Hematol 2013; 88:539.</a></li></ol></div><div id="topicVersionRevision">Topic 118011 Version 10.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16042682" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Diagnostic criteria for monoclonal B-cell lymphocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16042682" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Diagnostic criteria for monoclonal B-cell lymphocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24345750" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Monoclonal B-cell lymphocytosis in healthy blood donors: an unexpectedly common finding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20090778" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25295254" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : New insights into monoclonal B-cell lymphocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20839335" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Non-CLL-like monoclonal B-cell lymphocytosis in the general population: prevalence and phenotypic/genetic characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12091358" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19029437" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The immunoglobulin gene repertoire of low-count chronic lymphocytic leukemia (CLL)-like monoclonal B lymphocytosis is different from CLL: diagnostic implications for clinical monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19420353" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Increased frequency (12%) of circulating chronic lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32203143" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Risk of serious infection among individuals with and without low count monoclonal B-cell lymphocytosis (MBL).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12599176" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : B-cell monoclonal lymphocytosis and B-cell abnormalities in the setting of familial B-cell chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12239136" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33512457" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19709083" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Monoclonal B-cell lymphocytosis in first-degree relatives of patients with sporadic (non-familial) chronic lymphocytic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20855867" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Inherited genetic susceptibility to monoclonal B-cell lymphocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29674426" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19725826" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Common community acquired infections and subsequent risk of chronic lymphocytic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23285188" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Common infectious agents and monoclonal B-cell lymphocytosis: a cross-sectional epidemiological study among healthy adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18957521" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Hematopoietic malignancies associated with viral and alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14630808" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Monoclonal CD5+ and CD5- B-lymphocyte expansions are frequent in the peripheral blood of the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29540348" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20839333" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Different biology and clinical outcome according to the absolute numbers of clonal B-cells in monoclonal B-cell lymphocytosis (MBL).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23844084" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Combined patterns of IGHV repertoire and cytogenetic/molecular alterations in monoclonal B lymphocytosis versus chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19946263" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Single-cell analysis reveals oligoclonality among 'low-count' monoclonal B-cell lymphocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18687638" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21876118" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23596047" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22224978" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Monoclonal B-cell lymphocytosis is closely related to chronic lymphocytic leukaemia and may be better classified as early-stage CLL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26200345" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Non-coding recurrent mutations in chronic lymphocytic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22461140" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Analysis of SF3B1 mutations in monoclonal B-cell lymphocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23633543" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Clinical implications of the molecular genetics of chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20971821" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Differentiating chronic lymphocytic leukemia from monoclonal B-lymphocytosis according to clinical outcome: on behalf of the GIMEMA chronic lymphoproliferative diseases working group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10586211" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Natural history of early chronic lymphocytic leukemia. A single institution study with emphasis on the impact of disease-progression on overall survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21836611" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Survival of patients with clinically identified monoclonal B-cell lymphocytosis (MBL) relative to the age- and sex-matched general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22781591" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36418344" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The risk of coronavirus disease 2019 (COVID-19) among individuals with monoclonal B cell lymphocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33876228" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26310541" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Risk of non-hematologic cancer in individuals with high-count monoclonal B-cell lymphocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21993686" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Analysis of NOTCH1 mutations in monoclonal B-cell lymphocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21233839" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : CLL-like B-lymphocytes are systematically present at very low numbers in peripheral blood of healthy adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17638670" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Cytogenetic aberrations and immunoglobulin VH gene mutations in clinically benign CD5- monoclonal B-cell lymphocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24300853" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Clonal B-cell lymphocytosis exhibiting immunophenotypic features consistent with a marginal-zone origin: is this a distinct entity?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19438485" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25471173" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Prospective study of prognostic factors in asymptomatic patients with B-cell chronic lymphocytic leukemia-like lymphocytosis: the cut-off of 11 × 10(9)/L monoclonal lymphocytes better identifies subgroups with different outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23429376" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Bone marrow histology in monoclonal B-cell lymphocytosis shows various B-cell infiltration patterns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21261685" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Occult B-cell lymphoproliferative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12147660" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Incidental findings in pelvic lymph nodes at radical prostatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15832096" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Incidental and concurrent malignant lymphomas discovered at the time of prostatectomy and prostate biopsy: a study of 29 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15531231" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Hepatic resection for incidentaloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17917966" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Clinical outcome of incidental pelvic node malignant B-cell lymphomas discovered at the time of radical prostatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21546505" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Reassessment of small lymphocytic lymphoma in the era of monoclonal B-cell lymphocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18679371" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Occurrence of donor-derived CLL 8 years after sibling donor SCT for CML.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18021093" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Bioethical considerations of monoclonal B-cell lymphocytosis: donor transfer after haematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22168404" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Systematic donor blood qualification by flow cytometry would have been able to avoid CLL-type MBL transmission after unrelated hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17961190" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Monoclonal B-cell lymphocytosis in blood donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8624279" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Blood transfusion as a risk factor for non-Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11319177" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Blood transfusions and risk of non-Hodgkin's lymphoma subtypes and chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25174025" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Medical history, lifestyle, family history, and occupational risk factors for chronic lymphocytic leukemia/small lymphocytic lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23553682" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Total body computed tomography scan in the initial work-up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter O-CLL1-GISL study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
